ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: 4 days ago, 3:24AM

228.20

3.06 (1.36%)

  • 1D 1.36%
  • 5D -0.02%
  • 1M -0.86%
  • 6M 16.39%
  • YTD 27.17%
  • 1Y 13.83%
  • 5Y 141.48%
Previous Close 225.14
Open 227.05
Volume 4,984,511
Avg. Volume (3M) 5,294,409
Market Cap 403,128,582,144
Price / Earnings (TTM) 108.67
Price / Earnings (Forward) 16.84
Price / Sales 7.19
Price / Book 50.46
52 Weeks Range
163.81 (-28%) — 244.81 (7%)
Earnings Date 31 Oct 2025
TTM Dividend Yield 2.12%
Profit Margin 7.31%
Operating Margin (TTM) 30.43%
Diluted EPS (TTM) 2.35
Quarterly Revenue Growth (YOY) 8.40%
Quarterly Earnings Growth (YOY) -6.10%
Total Debt/Equity (MRQ) 4,789.60%
Current Ratio (MRQ) 0.760
Operating Cash Flow (TTM) 16.40 B
Levered Free Cash Flow (TTM) 16.94 B
Return on Assets (TTM) 8.34%
Return on Equity (TTM) 88.40%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bearish
Drug Manufacturers - General (Global) Bullish Bearish
Stock AbbVie Inc. Bullish Bullish

AIStockmoo Score

-0.5
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -0.5
Technical Moving Averages -2.5
Technical Oscillators -0.5
Average -0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ABBV 403 B 2.12% 108.67 50.46
JNJ 449 B 1.33% 17.97 5.71
PFE 142 B 3.42% 13.17 1.58
GSK 95 B 0.83% 13.39 4.42
BMY 92 B 2.70% 18.13 5.34
LLY 787 B 0.32% 43.02 40.22

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 74.87%
52 Weeks Range
163.81 (-28%) — 244.81 (7%)
Price Target Range
222.00 (-2%) — 284.00 (24%)
High 284.00 (Piper Sandler, 24.45%) Buy
Median 247.50 (8.46%)
Low 222.00 (Evercore ISI Group, -2.72%) Buy
Average 249.90 (9.51%)
Total 9 Buy, 1 Hold
Avg. Price @ Call 224.00
Firm Date Target Price Call Price @ Call
Guggenheim 20 Oct 2025 242.00 (6.05%) Buy 232.06
Raymond James 17 Oct 2025 250.00 (9.55%) Buy 229.57
Piper Sandler 10 Oct 2025 284.00 (24.45%) Buy 230.50
12 Aug 2025 231.00 (1.23%) Buy 198.64
B of A Securities 03 Oct 2025 251.00 (9.99%) Hold 233.91
Evercore ISI Group 22 Sep 2025 222.00 (-2.72%) Buy 222.59
Berenberg 17 Sep 2025 270.00 (18.32%) Buy 220.81
JP Morgan 16 Sep 2025 235.00 (2.98%) Buy 216.26
Cantor Fitzgerald 15 Sep 2025 245.00 (7.36%) Buy 217.61
BMO Capital 12 Sep 2025 240.00 (5.17%) Buy 218.34
Wells Fargo 12 Sep 2025 260.00 (13.94%) Buy 218.34
Show more

No data within this time range.

  • 3M
Date Type Details
29 Oct 2025 Announcement The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
29 Oct 2025 Announcement AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
28 Oct 2025 Announcement Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
21 Oct 2025 Announcement The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
20 Oct 2025 Announcement RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
17 Oct 2025 Announcement AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
13 Oct 2025 Announcement U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
13 Oct 2025 Announcement AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
09 Oct 2025 Announcement SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
06 Oct 2025 Announcement AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
02 Oct 2025 Announcement AbbVie to Host Third-Quarter 2025 Earnings Conference Call
01 Oct 2025 Announcement Natrelle® Awarded Supplier Agreement from Vizient
30 Sep 2025 Announcement AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
30 Sep 2025 Announcement AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
29 Sep 2025 Announcement AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
29 Sep 2025 Announcement AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
26 Sep 2025 Announcement AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
25 Sep 2025 Announcement Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
23 Sep 2025 Announcement Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
09 Sep 2025 Announcement BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
05 Sep 2025 Announcement AbbVie Declares Quarterly Dividend
03 Sep 2025 Announcement AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
03 Sep 2025 Announcement Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
02 Sep 2025 Announcement AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
25 Aug 2025 Announcement AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
21 Aug 2025 Announcement AbbVie Announces Positive Topline Results from Second Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
19 Aug 2025 Announcement AbbVie Completes Acquisition of Capstan Therapeutics
19 Aug 2025 Announcement SkinMedica® Unveils Its Newest Hydration Hero
12 Aug 2025 Announcement AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
06 Aug 2025 Announcement Get Ready, JUVÉDERM® Day is Calling!
05 Aug 2025 Announcement Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
Show more
TTM Dividend Yield 2.12%
5Y Average Dividend Yield 3.81%
Payout Ratio 268.80%
Expected Next Dividend Payment Feb 2026
Ex Date Announcement Date Payment Date Details
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Cash
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Cash
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Cash
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Cash
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria